-
Nanjing Rongjiekang RC1416 dual antibody ha<₹s obtained 2 clinical trial licenses againTime of issue : 2025- 01-03Recently, Nanjing RegeneCore Bioσσtechnology Co., Ltd.'s RC1416 projφ×&ect has consecutively obtained Inγ∞®αvestigational New Dr±£≥ug (IND) approvals fro$♥m the National Medical Products Adminisש€tration's Center for Drug Evaluation (C φ DE) for indications ₩€☆of atopic dermatitis (AD) and chr'∞®onic obstructive pul≈★monary disease (COPD). The expansion of☆±Ω these indications has further≈Ω diversified the cli₩£nical application scenarios of RC1416 injection,♣× providing better treatment options for more pa© tients..
-
融捷集團：競逐新賽道(dào)，勇攀生(shēng)命科(kē)技(jì)高(gāo)峰Time of issue : 2024- 12-02近(jìn)日(rì)，南京博爾迪生物科技有限公司發布的(de)一(yī♣←)則招募中重度哮喘患者的(de)消息引人(±£★rén)關注。原來(lái)，由融捷康自↑★☆(zì)研的(de)國(guó)內(nèi)首個(gè)自(zì)免雙特異性納米抗體(tǐ)藥物€π"(wù)——RC1416注射液，正在全國(guó)數£§(shù)十家(jiā)知(zhī)名醫(yī)院開(kāi)展臨床研究 σ。這(zhè)款雙抗藥品在藥效、安全性和(hé)成藥性等多(du☆☆♠ō)重指标上(shàng)具有(yǒu)較好(hǎo)∞✘的(de)優勢，未來(lái)有(yǒu)望成為(wèi)中重度✔♠哮喘患者的(de)福音(yīn)。
-
Recruitment of Patients with'₩• Moderate to Severe AsthmaTime of issue : 2024- 11-26RC1416 injection, developed by Nanjing Re•'₩≠geneCore Biotech Co.,Ltd, is currently underg&>♥®oing a Phase Ib clinical study to∞£↔ "evaluate the safety, tolerabilitγ ≤y, pharmacokinetics, p≠Ωharmacodynamics, immunogenicity, and prelim™ inary effectiveness of RC1≥÷416 injection in patients with ≈☆moderate to severe asthma♠∞." The lead institution ↑✘Ωπfor this study is the China-Japan Frieγ♥↔ndship Hospital in Beijing, and i©Ω★t is simultaneously being conducted at '✔dozens of renowned hospitals across the cou✘£Ω'ntry.
-
Lv Xiangyang Visited Nanjing Rege&∞necore and Thoth Inst♣λ₹itutesTime of issue : 2024- 09-19Lv Xiangyang visited Nanjing Regenecore & ₩©; Thoth Institutes, ass£←essing developments & fu'"ture development direction.
TEL：
Address: Room 07 Building 16 Tr∞βeehouse, No. 73, Tanmi Road, Jia• ±ngbei New District, Nanjing
Enterprise email：rjk@regenecore.com
WeChat cooperative consultatioεπεn
You are the th visitor
025-58608860 
Contact 